Skip to main content

Change at the top for CDMOs

Two of the major global pharmaceutical CDMOs, Lonza and Alcami, have announced the appointments of new CEOs in early June. There have also been changes in senior positions at Corden Pharma and, imminently, at Cambrex.

Evonik expands in pharma in Germany

Evonik, which is one of the world’s largest pharmaceutical CDMOs, has announced the €25 million first stage of a long-term programme to expand API and advanced intermediates capacity at its sites in Dossenheim and Hanau, Germany. This should be completed by mid-2021 and the whole project should be finalised prior to 2024.

Subscribe to CDMO

 

 

 

AMRI banner advert